THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 113 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,328,244 | -34.0% | 269,785 | -20.8% | 0.00% | -100.0% |
| Q2 2023 | $3,525,200 | -3.4% | 340,599 | +1.2% | 0.00% | 0.0% |
| Q1 2023 | $3,650,233 | -17.8% | 336,427 | -15.0% | 0.00% | 0.0% |
| Q4 2022 | $4,442,929 | -34.9% | 395,983 | -41.1% | 0.00% | 0.0% |
| Q3 2022 | $6,822,000 | +29.2% | 672,859 | +15.4% | 0.00% | 0.0% |
| Q2 2022 | $5,282,000 | -43.4% | 583,029 | -40.3% | 0.00% | -50.0% |
| Q1 2022 | $9,335,000 | +145.7% | 976,373 | +184.0% | 0.00% | +100.0% |
| Q4 2021 | $3,799,000 | +68.7% | 343,791 | +13.0% | 0.00% | – |
| Q3 2021 | $2,252,000 | -46.1% | 304,257 | +5.7% | 0.00% | -100.0% |
| Q2 2021 | $4,179,000 | -27.2% | 287,759 | +2.4% | 0.00% | 0.0% |
| Q1 2021 | $5,737,000 | -7.6% | 281,120 | -19.6% | 0.00% | -50.0% |
| Q4 2020 | $6,210,000 | +33.3% | 349,509 | +10.9% | 0.00% | +100.0% |
| Q3 2020 | $4,660,000 | -33.5% | 315,165 | -5.6% | 0.00% | -50.0% |
| Q2 2020 | $7,010,000 | +78.2% | 333,945 | +96.2% | 0.00% | +100.0% |
| Q1 2020 | $3,934,000 | +30.3% | 170,210 | +45.9% | 0.00% | 0.0% |
| Q4 2019 | $3,020,000 | +31.0% | 116,648 | -1.4% | 0.00% | 0.0% |
| Q3 2019 | $2,305,000 | -42.4% | 118,329 | -51.7% | 0.00% | 0.0% |
| Q2 2019 | $4,005,000 | -33.6% | 245,218 | -7.8% | 0.00% | -50.0% |
| Q1 2019 | $6,028,000 | +0.3% | 265,889 | +13.2% | 0.00% | 0.0% |
| Q4 2018 | $6,009,000 | -16.1% | 234,818 | +7.1% | 0.00% | 0.0% |
| Q3 2018 | $7,166,000 | +42.0% | 219,343 | -1.4% | 0.00% | +100.0% |
| Q2 2018 | $5,047,000 | -55.7% | 222,525 | -52.7% | 0.00% | -66.7% |
| Q1 2018 | $11,403,000 | +106.9% | 470,217 | +137.9% | 0.00% | +200.0% |
| Q4 2017 | $5,512,000 | -37.3% | 197,618 | -23.0% | 0.00% | -50.0% |
| Q3 2017 | $8,793,000 | -7.7% | 256,808 | +7.4% | 0.00% | 0.0% |
| Q2 2017 | $9,528,000 | +1.0% | 239,176 | -6.6% | 0.00% | -33.3% |
| Q1 2017 | $9,430,000 | +409.5% | 256,110 | +341.2% | 0.00% | +200.0% |
| Q4 2016 | $1,851,000 | +94.0% | 58,048 | +120.6% | 0.00% | – |
| Q3 2016 | $954,000 | +165.0% | 26,312 | +65.7% | 0.00% | – |
| Q2 2016 | $360,000 | +31.9% | 15,882 | +9.2% | 0.00% | – |
| Q1 2016 | $273,000 | -11.7% | 14,547 | -22.8% | 0.00% | – |
| Q4 2015 | $309,000 | +87.3% | 18,835 | +25.3% | 0.00% | – |
| Q3 2015 | $165,000 | -29.5% | 15,030 | +104.6% | 0.00% | – |
| Q2 2014 | $234,000 | – | 7,346 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |